---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-031008"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:29:54.229966+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics pauses Phase 3 enrollment in epetraborole trial after efficacy concern

## Summary
- Voluntary pause of Phase 3 enrollment in EBO-301 trial for treatment-refractory MAC lung disease.
- Blinded aggregate analysis showed potentially lower than expected efficacy; no safety concerns cited.
- Phase 2 part completed enrollment with 80 patients; Phase 3 had enrolled nearly 100 patients to date.
- Enrolled patients allowed to continue; topline Phase 2 data expected summer 2024.

## SEC filing metadata
- accession: 0001193125-24-031008
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312524031008/0001193125-24-031008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312524031008/d744326d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-031008
- JSON: https://secwatch.observer/filing/0001193125-24-031008.json
- Plain text: https://secwatch.observer/filing/0001193125-24-031008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.